-
3 weeks ago | 
lupusnewstoday.com | Lindsey Shapiro
People with systemic lupus erythematosus (SLE) who have antibodies that target the mitochondrial transcription factor A (TFAM) protein are more likely to develop certain blood clotting complications, a study found. The antibodies were a risk factor for blood clots, or thrombotic events, even when accounting for other factors that could play a role, such as smoking or the presence of other types of self-reactive antibodies (autoantibodies) linked to SLE.
-
3 weeks ago | 
lupusnewstoday.com | Lindsey Shapiro
October 23, 2023 by Lindsey Shapiro Lupus Therapeutics to support development of NK cell therapy Lupus Therapeutics will partner with Nkarta to advance the development of NKX019, Nkarta’s investigational natural killer (NK) cell therapy, for people with treatment-resistant lupus nephritis, a serious complication of lupus that features kidney damage and dysfunction. The U.S. Food and Drug Administration (FDA) recently cleared the launch…
-
1 month ago | 
lupusnewstoday.com | Margarida Maia
May is Lupus Awareness Month, and the Lupus Foundation of America is calling on supporters to join efforts to bring attention to lupus, an autoimmune disease whose symptoms are not always readily apparent. The focus of this year’s awareness month is “Make Lupus Visible” — given that the chronic condition is often invisible to others. For World Lupus Day on May 10, the World Lupus Federation, a global coalition, will also be pushing for greater awareness and more resources for patients.
-
1 month ago | 
lupusnewstoday.com | Marisa Wexler
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to FT819, a cell therapy Fate Therapeutics is developing to treat lupus. An RMAT designation is awarded to treatments for serious conditions that have shown promise in early clinical testing.
-
2 months ago | 
lupusnewstoday.com | Patricia Inacio |Steve Bryson |Katherine Poinsatte |Andrea Lobo
The U.S. Food and Drug Administration (FDA) has agreed to review an application by Roche seeking approval of obinutuzumab for the treatment of lupus nephritis, a lupus complication marked by kidney inflammation and damage. Developed by Roche’s subsidiary Genentech and Biogen, obinutuzumab is an antibody-based treatment, already approved for certain blood cancers, that was found in a clinical trial to ease symptoms of kidney disease in lupus nephritis patients.
-
Feb 20, 2025 | 
lupusnewstoday.com | Andrea Lobo |Margarida Maia |Katherine Poinsatte |Steve Bryson
The U.S. Food and Drug Administration (FDA) has granted fast track status to ADI-001, Adicet Bio’s CAR T-cell therapy for systemic lupus erythematosus (SLE) that’s resistant to available treatments, the company announced in a press release. The designation follows the FDA’s award last year of fast track status for lupus nephritis, a common complication of lupus marked by kidney damage and inflammation.
-
Jan 20, 2025 | 
lupusnewstoday.com | Candace J. Semien |Marisa Zeppieri |Kristiana Page |Kellie McRae
Near the end of 2024, the support group Lupus in Color posted the following “lupus serenity prayer” on Instagram:“God, grant me the serenity to accept the changes and challenges of living with lupus, the courage to face each day with strength, and the wisdom to do what’s good for my mind, body, and soul as I seek the support and treatment I need for a healthier life.”This prayer was written by Lupus in Color founder Racquel Dozier. It asks for serenity, courage, and wisdom.
-
Jan 16, 2025 | 
lupusnewstoday.com | Katherine Poinsatte |Margarida Maia |Patricia Inacio |Andrea Lobo
Caribou Biosciences has launched a Phase 1 clinical trial to evaluate the safety and efficacy of CB-010, its CAR T-cell therapy for lupus that affects the kidneys and other organs. CB-010 is being developed as a treatment for people with lupus nephritis, a common complication of lupus that causes kidney damage and inflammation, and those with extrarenal lupus, in which other tissues and organs are affected.
-
Dec 11, 2024 | 
lupusnewstoday.com | Marisa Zeppieri |Marisa Wexler |Candace J. Semien
As another year draws to a close, I find myself reflecting not only on the milestones of the past 12 months, but also on the journey that’s brought me to this moment. When I look back at the years when I was so sick, growing up with unexplainable pain and fatigue, I never imagined I would make it this far. I was just a child when I first began to feel the weight of my illness, and by the time I was diagnosed with lupus in my 20s, the prognosis seemed grim.
-
Nov 27, 2024 | 
lupusnewstoday.com | Marisa Zeppieri |Candace J. Semien
It’s no secret that living with lupus or other chronic illnesses often feels like a constant game of tug-of-war. One part of us aches to chase after our dreams, tackle projects, and seize life, while the other part is continually reminded of the need to slow down, conserve energy, and avoid flares. I often liken it to an emotional and physical seesaw, one that few understand unless they’ve walked our road. The hardest part of this balancing act is the unpredictability.